BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$6.18 USD
+0.07 (1.15%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $6.21 +0.03 (0.49%) 7:58 PM ET
F Value C Growth C Momentum D VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 1 - 20 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Top 23 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pediatric Population Offers Important Growth Potential for Orladeyo - Growth Trajectory Continues; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Can Continue Near-Term Growth Strategy - Oral Differentiation; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for BCRX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biocryst?s Structure-Based Drug Design Reflective of the Next Chapter of the Complement Mediated Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Near-Term Growth Strategy and Upside From Drug Discovery RD Day; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Orladeyo Growth Trajectory Continues to Define Near-Term; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Growth and Global Scope?Setting Foundation For Broader Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Expansion Met With Separate BCX10013 Pipeline Questions; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
BCX10013 Reflects Nimble Pivot For Complement Pipeline; Data Expected 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 5.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
What?s Next? Considerations for the Complement-Mediated Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
FDA Lifts BCX9930 Partial Clinical Hold While Orladeyo Delivers in HAE
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Tale of Two Cities-As Orladeyo Expands, BCX9930 Re-Evaluates Dosing Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Expansion Within Oral HAE, and BCX9930 Pipeline in a Molecule Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Asserts HAE Positioning - Planting Flag for Oral Prophylaxis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Launch Reflects Oral Demand-Global HAE Upside on Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 12.50
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Impetus Supports Demand for Oral HAE Prophylactic; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Off to the Races, Along With Pivotal PNH Trials Expected 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00